Whan In PharmLtd Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Whan In PharmLtd has been growing earnings at an average annual rate of 8.1%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 9% per year. Whan In PharmLtd's return on equity is 7.9%, and it has net margins of 12%.
Belangrijke informatie
8.1%
Groei van de winst
8.1%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 11.3% |
| Inkomstengroei | 9.0% |
| Rendement op eigen vermogen | 7.9% |
| Nettomarge | 12.0% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Did Whan In Pharm Co.,Ltd. (KRX:016580) Use Debt To Deliver Its ROE Of 7.8%?
Mar 15
Here's Why I Think Whan In PharmLtd (KRX:016580) Might Deserve Your Attention Today
Feb 25Whan In Pharm Co.,Ltd.'s (KRX:016580) 1.6% Dividend Yield Looks Pretty Interesting
Feb 04
What Is The Ownership Structure Like For Whan In Pharm Co.,Ltd. (KRX:016580)?
Jan 14Why You Might Be Interested In Whan In Pharm Co.,Ltd. (KRX:016580) For Its Upcoming Dividend
Dec 24Does Whan In Pharm Co.,Ltd. (KRX:016580) Create Value For Shareholders?
Dec 11Whan In PharmLtd's (KRX:016580) Shareholders Are Down 33% On Their Shares
Nov 20Opbrengsten en kosten
Hoe Whan In PharmLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 242,456 | 29,191 | 66,280 | 636 |
| 31 Mar 24 | 236,463 | 31,727 | 65,688 | 736 |
| 31 Dec 23 | 230,394 | 29,774 | 65,345 | 1,072 |
| 30 Sep 23 | 224,164 | 27,469 | 64,946 | 1,358 |
| 30 Jun 23 | 214,684 | 25,886 | 63,616 | 3,349 |
| 31 Mar 23 | 205,629 | 22,712 | 63,962 | 3,564 |
| 31 Dec 22 | 198,935 | 23,921 | 63,014 | 3,331 |
| 30 Sep 22 | 191,764 | 22,517 | 63,041 | 4,150 |
| 30 Jun 22 | 187,376 | 23,764 | 61,904 | 2,367 |
| 31 Mar 22 | 181,398 | 25,042 | 58,493 | 2,540 |
| 31 Dec 21 | 177,776 | 26,660 | 56,942 | 2,659 |
| 30 Sep 21 | 176,995 | 27,456 | 55,638 | 1,838 |
| 30 Jun 21 | 175,353 | 28,898 | 53,945 | 1,670 |
| 31 Mar 21 | 174,884 | 26,901 | 53,735 | 1,577 |
| 31 Dec 20 | 171,705 | 23,388 | 52,431 | 3,312 |
| 30 Sep 20 | 166,094 | 21,795 | 50,313 | 3,288 |
| 30 Jun 20 | 163,538 | 19,548 | 50,047 | 3,197 |
| 31 Mar 20 | 161,934 | 17,492 | 49,730 | 2,968 |
| 31 Dec 19 | 159,177 | 18,696 | 49,773 | 993 |
| 30 Sep 19 | 157,489 | 19,627 | 49,489 | 610 |
| 30 Jun 19 | 156,534 | 19,971 | 49,136 | 524 |
| 31 Mar 19 | 155,832 | 23,436 | 49,164 | 527 |
| 31 Dec 18 | 154,664 | 21,518 | 49,573 | 648 |
Kwaliteitswinsten: A016580 has high quality earnings.
Groeiende winstmarge: A016580's current net profit margins (12%) are lower than last year (12.1%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: A016580's earnings have grown by 8.1% per year over the past 5 years.
Versnelling van de groei: A016580's earnings growth over the past year (12.8%) exceeds its 5-year average (8.1% per year).
Winst versus industrie: A016580 earnings growth over the past year (12.8%) did not outperform the Pharmaceuticals industry 21.9%.
Rendement op eigen vermogen
Hoge ROE: A016580's Return on Equity (7.9%) is considered low.